# CRISPR THERAPEUTICS AG (CRSP) · Edgar & Edgarette company card

> Crispr Therapeutics (CRSP) saw revenue fall 90.6% in FY2025 to $4 million, operating margin -18934% against a -15.8% median for biological products, (no diagnostic substances), equity 84.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1674416 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CRSP) · [JSON](https://www.pops4.com/boards/company/CRSP.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $4M |
| Revenue growth, 1 year | -90.6% |
| Revenue growth per year | -75.1% |
| Operating margin | -18933.6% (prior year -1250.4%) |
| Net margin | -16569.8% |
| Operating cash flow | −$345M |
| Capital spending | $914,000 |
| Free cash flow | −$346M |
| Cash | $348M |
| Long-term debt | — |
| Total assets | $2.3B |
| Total equity | $1.9B |
| Equity ÷ assets | 84.8% |
| Return on equity | -30.3% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 6.42 (safe zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -18933.6% in FY2025; revenue is hard to predict: its 80% range is ±53%

## Edgarette's reading

Exposure: revenue $3.5M (FY2025). Experience: revenue down 90.6% on the year, down 75.1% a year over 4 years; operating margin -18933.6%, down from -1250.4%. Soundness: equity 84.8% of assets, return on equity -30.3%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.5M and $4.7M next year (method v4.1: its own 0-year record of growth weighed at 0% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1.3M to $5.1M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -18933.6% against a -15.8% median; growth -90.6% against 21.4%.

Range logged 2026-10-20, receipt 878bd2f6af80a685, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-10-19 ([filing](https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/0001193125-26-425243-index.htm))

## Recent filings

- 10-Q · filed 2026-11-02 · [filing](https://www.sec.gov/Archives/edgar/data/1674416/000119312526443665/0001193125-26-443665-index.htm)
- 8-K · filed 2026-11-02 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1674416/000119312526443644/0001193125-26-443644-index.htm)
- 8-K · filed 2026-10-19 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/0001193125-26-425243-index.htm)
- 10-Q · filed 2026-08-03 · [filing](https://www.sec.gov/Archives/edgar/data/1674416/000119312526330672/0001193125-26-330672-index.htm)
- 8-K · filed 2026-08-03 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1674416/000119312526330644/0001193125-26-330644-index.htm)
- 8-K · filed 2026-06-04 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1674416/000119312526257593/0001193125-26-257593-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001674416.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1674416

## Cite

POPS4, Edgar & Edgarette: CRISPR THERAPEUTICS AG (CRSP) company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/CRSP. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

